Sclerotherapy of esophageal varices: long-term results and determinants of survival.
Between 1980 and 1986, 177 patients underwent sclerotherapy by means of the flexible fiberoptic endoscope for bleeding esophageal varices. Of these, 129 were treated with serial sclerotherapy alone. The remaining 48 patients underwent liver transplantation after sclerotherapy; these are reported separately. Patients were classified by Child's criteria, by the severity of the initial bleeding episode as reflected by the urgency of treatment, and by the nature of the underlying liver disease. Long-term survival rates were markedly influenced by Child's classification, with 83% of the patients in class A, 45% of those in class B, and 20% of those in class C surviving beyond 36 months (p less than 0.001). Urgent treatment was associated with a poorer survival than was elective treatment (p less than 0.001). Survival was not influenced by underlying alcoholic liver disease as compared to a nonalcoholic liver disease. The majority of deaths occurred within the first 100 days after the initial treatment. Child's class B and C patients had the highest early mortality rates, particularly in an acute treatment setting. The most frequent causes of death included progressive liver failure and persistent hemorrhage. Sclerotherapy for bleeding esophageal varices may successfully control hemorrhage, but the influence of this treatment on long-term survival is limited. Hepatic reserve, indicated by Child's classification, is the major determinant of survival. Significant improvements in survival after variceal bleeding are intimately linked to improvement in liver function.
Garrett
K O
KO
Department of Surgery, University of Pittsburgh School of Medicine, PA 15261.
Reilly
J J
JJ
Schade
R R
RR
van Thiel
D H
DH
D000206:Actuarial Analysis; D000208:Acute Disease; D000328:Adult; D000368:Aged; D004724:Endoscopy / Q000379:methods; D004932:Esophageal and Gastric Varices / Q000145:classification / Q000401:mortality / Q000628:therapy*; D005260:Female; D005336:Fiber Optic Technology; D006471:Gastrointestinal Hemorrhage / Q000401:mortality / Q000628:therapy; D006801:Humans; D008107:Liver Diseases / Q000401:mortality / Q000601:surgery; D008297:Male; D008875:Middle Aged; D012597:Sclerosing Solutions / Q000627:therapeutic use*
D012597:Sclerosing Solutions